Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()

Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB–mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our object...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugolkov, Andrey, Qiang, Wenan, Bondarenko, Gennadiy, Procissi, Daniel, Gaisina, Irina, James, C. David, Chandler, James, Kozikowski, Alan, Gunosewoyo, Hendra, O'Halloran, Thomas, Raizer, Jeffrey, Mazar, Andrew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496477/
https://www.ncbi.nlm.nih.gov/pubmed/28672195
http://dx.doi.org/10.1016/j.tranon.2017.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496477/
https://www.ncbi.nlm.nih.gov/pubmed/28672195
http://dx.doi.org/10.1016/j.tranon.2017.06.003

Ejemplares similares